Review
Open access
Sep 2026
Recent advances in tumor-activated prodrug nanoparticles for cancer immunotherapy
Numerous therapeutic agents have been demonstrated to initiate antitumor immune responses, thereby driving significant progress in cancer immunotherapy. However, clinical translation is severely limited by persistent challenges, including systemic toxicity, the immunosuppressive tumor microenvironment (TME), and low na...
Guan-Ran Wang, Kun Du, Di-Kai Sun et al.
· Frontiers in Immunology · 0 citations